RecruitingPhase 1Phase 2NCT07629960

A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations

A Phase 1/2, Open-Label, Dose-Escalation, Dose-Enrichment, and Dose-Expansion Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of BLU-924 (SAR449336) as Monotherapy and Combination Therapy in Participants With Advanced Pancreatic Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer Harboring KRAS Mutations

Sponsor

Blueprint Medicines Corporation

Enrollment

265 participants

Start Date

Jun 4, 2026

Study Type

INTERVENTIONAL

Conditions

Advanced Solid Tumor Non-small Cell Lung Cancer Pancreatic Ductal Adenocarcinoma Colorectal Neoplasms

Summary

A first in human study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of BLU-924 / SAR449336, a pan-KRAS inhibitor, in participants with advanced Pancreatic Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer harboring KRAS mutations.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called BLU-924 for people with advanced solid tumor, colorectal neoplasms, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGBLU-924

Tablet

Locations(16)

Florida Cancer Specialists & Research Institute - Sarasota

Sarasota, Florida, United States

Moffitt Cancer Center

Tampa, Florida, United States

Mary Bird Perkins Cancer Center

Baton Rouge, Louisiana, United States

Massachusetts General Hospital - Main Campus

Boston, Massachusetts, United States

University of Michigan Medical School Rogel Cancer Center

Ann Arbor, Michigan, United States

Hackensack University Medical Center

Hackensack, New Jersey, United States

NYU Langone Health Perlmutter Cancer Center

New York, New York, United States

Tennessee Oncology, PLLC

Nashville, Tennessee, United States

The University of Texas MD Anderson Cancer Center - Texas Medical Center

Houston, Texas, United States

Next Oncology Virginia Cancer Specialist

Fairfax, Virginia, United States

Mi Cancer Center Barcelona (Pratia Sirius Barcelona)

Barcelona, Catalonia, Spain

Hospital Universitario Vall d'Hebron

Barcelona, Catalonia, Spain

Hospital General Universitrio Gregorio Maranon

Madrid, Madrid, Spain

Hospital Universitario 12 de Octubre

Madrid, Madrid, Spain

NEXT Oncology - Madrid

Pozuelo de Alarcón, Madrid, Spain

Clinica Universidad de Navarra (CUN)

Pamplona, Navarre, Spain

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07629960

Related Trials

Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

NCT0756215231 locations

Study of D3L-002 in Subjects With Advanced Solid Tumors

NCT07667842

A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)

NCT07190248195 locations

MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013)

NCT0743182772 locations

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

NCT06767514270 locations